Application of CoLD-CoP to Detecting Competitively and Cooperatively Binding Ligands
- PMID: 39334902
- PMCID: PMC11430148
- DOI: 10.3390/biom14091136
Application of CoLD-CoP to Detecting Competitively and Cooperatively Binding Ligands
Abstract
NMR utilization in fragment-based drug discovery requires techniques to detect weakly binding fragments and to subsequently identify cooperatively binding fragments. Such cooperatively binding fragments can then be optimized or linked in order to develop viable drug candidates. Similarly, ligands or substrates that bind macromolecules (including enzymes) in competition with the endogenous ligand or substrate are valuable probes of macromolecular chemistry and function. The lengthy and costly process of identifying competitive or cooperative binding can be streamlined by coupling computational biochemistry and spectroscopy tools. The Clustering of Ligand Diffusion Coefficient Pairs (CoLD-CoP) method, previously developed by Snyder and co-workers, detects weakly binding ligands by analyzing pairs of diffusion spectra, obtained in the absence and the presence of a protein. We extended the CoLD-CoP method to analyze spectra pairs (each in the presence of a protein) with or without a critical ligand, to detect both competitive and cooperative binding.
Keywords: cooperative/competitive ligand binding; diffusion spectroscopy (DOSY); fragment-based drug discovery (FBDD); nuclear magnetic resonance (NMR).
Conflict of interest statement
The authors declare no conflicts of interest.
Figures








Similar articles
-
Analysis of ligand-protein exchange by Clustering of Ligand Diffusion Coefficient Pairs (CoLD-CoP).J Magn Reson. 2015 Jun;255:44-50. doi: 10.1016/j.jmr.2015.03.005. Epub 2015 Mar 23. J Magn Reson. 2015. PMID: 25909645
-
Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy.Methods Enzymol. 2011;493:469-85. doi: 10.1016/B978-0-12-381274-2.00018-2. Methods Enzymol. 2011. PMID: 21371602
-
NMR-based fragment screening and lead discovery accelerated by principal component analysis.J Biomol NMR. 2019 Dec;73(12):675-685. doi: 10.1007/s10858-019-00279-9. Epub 2019 Sep 20. J Biomol NMR. 2019. PMID: 31541395
-
[NMR screening in fragment-based drug discovery].Yakugaku Zasshi. 2010 Mar;130(3):325-33. doi: 10.1248/yakushi.130.325. Yakugaku Zasshi. 2010. PMID: 20190517 Review. Japanese.
-
Fragment-based drug discovery using NMR spectroscopy.J Biomol NMR. 2013 Jun;56(2):65-75. doi: 10.1007/s10858-013-9740-z. Epub 2013 May 18. J Biomol NMR. 2013. PMID: 23686385 Free PMC article. Review.
References
-
- Austin D., Hayford T. Research and Development in the Pharmaceutical Industry. Congressional Budget Office; Washington, DC, USA: 2021.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources